mAb2-3

mAb2-3 is a human monoclonal antibody targeting the C-C chemokine receptor type 4 (CCR4), primarily developed to modulate regulatory T cells (Tregs) in the tumor microenvironment. Developed at the Dana-Farber Cancer Institute, the antibody exists in two isotypes: an IgG1 version that induces Treg depletion via antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), and an IgG4 version that blocks Treg migration to tumor sites by inhibiting CCL22/CCR4 interactions. Uniquely, mAb2-3 acts as an agonist that triggers CD25 shedding from Tregs through matrix metalloproteinase 9 (MMP-9) activation, thereby disrupting IL-2-mediated Treg survival. It has shown preclinical efficacy in restoring antitumor immunity in ovarian cancer models and is distinct from mogamulizumab in its conformational epitope recognition and agonist properties.

Other names

anti-CCR4 mAb2-3anti-CCR-4 mAb2-3anti-CCR 4 mAb2-3human anti-CCR4 mAb2-3